RxDoctor Payments DataLook up a doctor →

Heather Saran, DO

Endocrinology, Diabetes & Metabolism · Scottsdale, AZNPI 1245596444

Payments from drug & device makers

$13,708in general payments, 2019–2025

Across 428 payments — averaging $32.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mannkind Corporation$4K
  • Lilly USA, LLC$1K
  • Rhythm Pharmaceuticals, Inc.$1K
  • Corcept Therapeutics$812
  • Dexcom, Inc.$653
  • Novo Nordisk$653
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$1,70012%
  • Travel & lodging$1,75913%
  • Food & beverage$10,15674%
  • Education$340%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,708 in reported general payments places this provider in the 80th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

See all endocrinology, diabetes & metabolism providers in Arizona

Medicare billing

Part B allowed, 2024
$85,443
Medicare patients
283
Services billed
2,543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide93$146,970
JardianceEmpagliflozin60$76,242
Tresiba Flextouch U-200Insulin Degludec21$44,299
TrulicityDulaglutide27$41,338
MounjaroTirzepatide27$37,269
Lyumjev Kwikpen U-200Insulin Lispro-Aabc11$11,991
SynthroidLevothyroxine Sodium59$6,006
HumalogInsulin Lispro11$5,860
Novolog FlexpenInsulin Aspart13$3,022
Humalog Kwikpen U-100Insulin Lispro11$2,777
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$2,765
Levothyroxine Sodium190$2,084
Testosterone12$2,022
Nano 2nd Gen Pen NeedlePen Needle, Diabetic13$1,854
Hydrocortisone11$1,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$653$146,97093 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$1,300$84,46765 claims
Boehringer IngelheimJardiance$150$76,24260 claims
AbbVieSynthroid$434$6,00659 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$84$2,723208 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 148 endocrinology, diabetes & metabolism providers in Arizona.

Other endocrinology, diabetes & metabolism in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →